In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Prenatal screening describes tests that detect potential problems that affect the viability and development of the fetus using both less invasive and more invasive sampling techniques. GlobalData uses proprietary data and analytics to provide a comprehensive report on the prenatal screening devices market, including market shares of different players within Australia. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the prenatal screening market in Australia was Illumina followed by F. Hoffmann-La Roche, Ortho Clinical Diagnostics, Danaher, BGI Genomics, Thermo Fisher Scientific, PerkinElmer, Eurofins Scientific, Siemens and Abbott Laboratories.
This market includes the sub-segments Free Beta Human Chorionic Gonadotropin (hCG) Tests, Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests, Alpha-Fetoprotein (AFP) Tests, and Inhibin A Tests.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the prenatal screening devices market within Australia was expected to be over $10m in 2022.
For the latest complete market share analysis of prenatal screening device market in Australia, buy the report here.